IM Cannabis (IMCC) Cash from Financing Activities (2020 - 2026)
IM Cannabis (IMCC) recorded quarterly Cash from Financing Activities of -$680348.9 in Q1 2026, down 2194.86% quarter-over-quarter from $32477.1 in Q2 2025, and up 66.01% on a YoY basis from -$409827.0 in Q1 2025.
IM Cannabis (IMCC) Cash from Financing Activities (2020 - 2026) Analysis & Trends
IM Cannabis' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$680348.9 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 66.01% year-over-year to -$680348.9; the TTM figure through Mar 2026 stood at $104455.7 (down 92.31% YoY), while the FY2025 annual figure was $821780.9, down 70.59% from the prior year.
- Cash from Financing Activities was -$680348.9 for Q1 2026 at IM Cannabis, down from $32477.1 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $4.9 million in Q1 2023 to a low of -$3.2 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $720267.0 across 5 years, with a median of $32477.1 in 2025.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 268.24% in 2022, then soared 10232.79% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $1.4 million in 2022, then plunged by 101.99% to -$27177.8 in 2023, then jumped by 10232.79% to $2.8 million in 2024, then plunged by 98.82% to $32477.1 in 2025, then slumped by 2194.86% to -$680348.9 in 2026.
- The last three Cash from Financing Activities figures came in at -$680348.9 (Q1 2026), $32477.1 (Q2 2025), and -$2.0 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | IM Cannabis | 49,978.63 | -735,375.90 | 1.03 Mn | -680,348.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -680,348.91 |
| Mar 31, 2026 | -680,348.91 |
| Jun 30, 2025 | 32,477.06 |
| Jun 30, 2025 | 32,477.06 |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | -487,480.52 |
| Sep 30, 2024 | -487,480.52 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | -632,280.45 |
| Mar 31, 2024 | -632,280.45 |
| Dec 31, 2023 | -27,177.81 |
| Dec 31, 2023 | -27,177.81 |
| Sep 30, 2023 | -912,272.96 |
| Sep 30, 2023 | -912,272.96 |
| Jun 30, 2023 | 3.07 Mn |
| Jun 30, 2023 | 3.07 Mn |